Suppr超能文献

欧洲移植组织内器官(尤其是肾脏)的分配。

Allocation of organs, particularly kidneys, within Eurotransplant.

作者信息

Persijn G G

机构信息

Eurotransplant International Foundation, Leiden, The Netherlands.

出版信息

Hum Immunol. 2006 Jun;67(6):419-23. doi: 10.1016/j.humimm.2006.03.008. Epub 2006 Mar 30.

Abstract

Allocation of scarce donor organs is an important discussion topic among ethical, medical, and legal experts, the public at large, and politicians. Since 1996, a new kidney allocation system based on primarily medical and patient-oriented criteria was introduced in Eurotransplant (ET). This point-scoring system takes the following factors into account: HLA-A,B,DR mismatch, mismatch probability, waiting period, i.e., time on dialysis, distance between donor/transplantation center, and balance between import/export of the six participating countries. Extra points are given to high urgency patients and to children. During the first 9 years of the new ET kidney allocation system (ETKAS) almost 30,000 deceased donor kidneys have been allocated of which 22.3% have been transplanted without HLA-A,B,DR mismatches. Twice as many long-waiting patients, i.e., >5 years, have been transplanted as compared with the pre-ETKAS period. Also substantially more children and highly sensitized patients received kidney transplants. Importantly, the balances between import and export of donor kidneys among the different ET countries remained among very well-accepted levels. Finally, overall kidney transplant survival was 78% after 3 years and a significant HLA-matching effect was noticed, i.e., 83% at 3 years for the HLA-A,B,DR mismatched combinations. In conclusion, the new ETKAS has reached its aims and goals. The main problem remains, however, the continuing shortage of deceased donor kidneys.

摘要

稀缺供体器官的分配是伦理、医学和法律专家、广大公众以及政界人士热议的重要话题。自1996年起,欧洲移植组织(ET)引入了一种主要基于医学和患者导向标准的新肾脏分配系统。这种积分系统考虑了以下因素:HLA - A、B、DR错配、错配概率、等待期,即透析时间、供体/移植中心之间的距离,以及六个参与国进出口之间的平衡。高紧急需求患者和儿童可获得额外积分。在新的欧洲移植组织肾脏分配系统(ETKAS)实施的前9年里,已分配了近30000个 deceased donor kidneys,其中22.3%的移植未出现HLA - A、B、DR错配。与ETKAS实施前相比,等待时间较长(即超过5年)的患者接受移植的人数增加了一倍。接受肾脏移植的儿童和高敏患者也显著增多。重要的是,不同ET国家之间供体肾脏进出口的平衡仍处于非常可接受的水平。最后,肾脏移植3年后的总体存活率为78%,并且观察到了显著的HLA匹配效果,即HLA - A、B、DR错配组合在3年后的存活率为83%。总之,新的ETKAS实现了其目标。然而,主要问题仍然是 deceased donor kidneys持续短缺。 (注:“deceased donor kidneys”直译为“已故供体肾脏”,这里结合语境意译为“死亡供体肾脏”可能更合适,但按照要求保留原文未改动。)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验